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Background: The prognosis for patients diagnosed with non small cell 
lung cancer is poor and research efforts are being directed towards the 
development of novel research models to predict patterns of failure or 
success in non surgically treated patients with NSCLC. 
Objective: 1. To determine if there is a difference in the proportions of 
histological cell types between LTS the patients who live greater than 
3 years without surgery when compared to the patient population in the 
Thoracic Data Base (TDB). 2. To determine if there is a meaningful dif-
ference in the proportions of “B” symptoms in the LTS group. 
Methods: In a retrospective analysis of MD Anderson Cancer Center 
(MDACC) tumor registry, we identiﬁed all pts diagnosed with non 
small cell lung cancer (NSCLC) from 1991-2001. Those with surgi-
cal resection were excluded. In addition, we prospectively identiﬁed a 
reference group of NSCLC patients through the MDACC Thoracic date 
base (TDB) treated in our department since 2002. Histologic cell types 
were grouped according to: Adenocarcinoma (A), Bronchioloalveolar 
(BAC) Squamous (S), NSCLC, Not Otherwise Speciﬁed (NSC/NOS) 
and Large Cell Neuroendocrine (L) and the two databases were com-
pared for differences. Clinical records of all patients in the LTS group 
were reviewed for weight loss, fever, and fatigue. 
Results: 14,764 patients were seen with a primary diagnosis of 
NSCLC. 5,114 received initial treatment at MDACC. 1,925 had 
surgery. LTS was achieved in 294 of 3,189 (9.2%) who were treated 
with radiation, chemotherapy or combined modality therapy. Median 
survival for LTS was 5.2 years. Histologic subtyping was available for 
in all 294 LTS pts and 2,034 TDB pts. Histology subtypes are shown in 
Table I below.
Histology
TDB  
(Total=
2034)
Number of 
Patients
Percent-
age
LTS  
(Total=
293)
Number  
of Pts
Percentage
Adeno  1020  50.1%  128 43.7%
Adeno/BAC  90 4.4%  11 3.8%
Squamous  384 18.9%  72 24.6%
NSC/NOS  492 24.2%  69 23.5%
Large cell  48 2.4%  13 4.4%
In the LTS arm the rates of “B” symptoms were: Fever, 15/294(5.1%), 
Fatigue, 23/294(7.8%), No symptoms 255/294 (86.7%), weight loss 
104/294(35.4%), no weight loss 191/294 (64.6%). 
Conclusions: Squamous subtype was over-represented in LTS pts 
compared to Adenocarcinoma. (chi-square test p=0.0274) There was 
no apparent excess in BAC as might have been expected. Although the 
numbers are small, Large Cell histology was also higher than expected. 
Discussion: Histologic subtypes of NSCLC have taken on increasing 
importance in the era of targeted therapy. Our analysis suggests that 
prognostic models should increasingly include histology and presence 
or absence of “B” symptoms.
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Introduction: Solitary brain metastases occur in about 50% of patients 
with brain metastases from non small cell lung cancer. The standard 
therapy is surgical resection or stereotactic radiosurgery plus whole 
brain radiotherapy. The optimal treatment for the primary site of newly 
diagnosed non small cell lung cancer with solitary brain metastases is 
not well deﬁned.
Purpose: to evaluate the outcome of treatment for patients with newly 
diagnosis advanced non small cell lung cancer with isolated single 
synchronous brain metastases. 
Material and Methods: A total of 22 patients with non small cell lung 
cancer and solitary brain metastases were included. All patients had 
extensive tumour non small cell lung cancer with involved mediasti-
nal lymph nodes. 4 patients received treatment of their primary lung 
cancer using radiotherapy, 6 patients treated with chemotherapy and 12 
patients treated with both chemotherapy and radiotherapy.
The treatment of brain metastases was as follows: 14 patients under-
went surgery resection and postoperative whole brain radiotherapy, 4 
had surgical resection alone and 4 treated with radiotherapy alone. Sur-
vival was measured from the date of the ﬁrst treatment for malignancy.
Results: Overall survival from time of lung cancer diagnoses were 1 
year survival rate 36, 3%, 2-year 9%. The better overall survival was 
achieved in patients treated with chemo and radiotherapy. A total of 6 
(27, 2%) patients had failure in brain, including 3 patients who receiv-
ing whole brain irradiation alone.
Conclusion: Aggressive therapy for both, primary site of non small cell 
lung cancer and the brain metastases may provide a survival advan-
tages. Better local control of single brain metastases was achieved with 
a combination of whole brain radiotherapy with surgical resection.
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Background: Long term survival (LTS) is the ultimate goal of success-
ful treatment in non small cell lung cancer (NSCLC). Unfortunately, 
surgery is not an option for most pts and LTS is less likely without 
surgery. Although performance status (PS), gender, and stage are estab-
lished key prognostic variables, more information is needed regarding 
other predictors of success or failure. 
Objective: We analyzed the impact of tumor location in pts with 
NSCLC who lived 3 years or longer without surgery.
Methods: Using the MDACC Thoracic Database (TDB), we reviewed 
records of all pts with NSCLC diagnosed from 1991-2001 excluding 
those having pneumonectomy, lobectomy, segmental, or wedge resec-
tion. We analyzed tumors according to upper, lower, middle, or central 
location and compared them to our ongoing prospective TDB. 
